前列腺小细胞癌诊疗研究进展  

Research progress in diagnosis and treatment of small cell prostate cancer

作　　者：孙奕飞 张劲松[1] 李宁[1] 王海峰 左毅刚[1] 王剑松[1] SUN Yifei;ZHANG Jinsong;LI Ning;WANG Haifeng;ZUO Yigang;WANG Jiansong(Department of Urology»Second Affiliated Hospital of Kunming Medical University,Yunnan.Institute of Urology,Kunming,650101,China)

机构地区：[1]昆明医科大学第二附属医院泌尿外科云南省泌尿外科研究所,昆明650101

出　　处：《临床泌尿外科杂志》2021年第4期325-329,共5页Journal of Clinical Urology

基　　金：国家自然科学基金资助项目(No:81660423,81660422);云南省科技厅-昆明医科大学联合基础研究面上项目(No:2017FE468-059)。

摘　　要：前列腺小细胞癌(SCC)是前列腺癌的一种罕见的变体,也是最具侵袭性的恶性肿瘤之一。尽管有新一代AR途径抑制剂(阿比特龙、恩杂鲁胺)来治疗去势抵抗性前列腺癌,然而随着疾病进一步发展为神经内分泌性前列腺癌(NEPC)并严重影响患者预后,于是针对其最常见变体前列腺SCC的研究不断深入,但其发病机制及治疗手段等仍存在争议。本文以前列腺SCC患者为目标人群,总结其病理及临床特征,对发病机制、治疗方案的最新研究进展开展论述,以供后来更深入的研究。Prostate small cell carcinoma(SCC) is a rare variant of prostate cancer and one of the most aggressive malignancies. Although there is a new generation of AR pathway inhibitors(abiraterone, enzalutamide) to treat castration-resistant prostate cancer, the disease further develops to neuroendocrine prostate cancer(NEPC) and seriously affects the patient’s prognosis. The research of SCC in the prostate is continuously deepened, but its pathogenesis and treatment methods are still controversial. In this paper, we take patients with prostate SCC as the target population, summarize their pathological and clinical characteristics, and discuss the latest research progress in pathogenesis and treatment options for further research in the future.

关 键 词：前列腺肿瘤 小细胞癌 神经内分泌 

分 类 号：R737.25[医药卫生—肿瘤]